Galena Biopharma, Inc. (NASDAQ:GALE) shares fell 6.7% during mid-day trading on Tuesday . The company traded as low as $0.26 and last traded at $0.28. 1,327,012 shares traded hands during trading, an increase of 23% from the average session volume of 1,082,940 shares. The stock had previously closed at $0.30.
Separately, Maxim Group reaffirmed a “hold” rating on shares of Galena Biopharma in a report on Wednesday, August 9th.
Several large investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in shares of Galena Biopharma during the first quarter valued at $976,000. Vanguard Group Inc. lifted its holdings in Galena Biopharma by 1.0% in the second quarter. Vanguard Group Inc. now owns 1,332,434 shares of the biotechnology company’s stock valued at $774,000 after acquiring an additional 13,302 shares during the period. Vaughan David Investments Inc. IL lifted its holdings in Galena Biopharma by 6,545.7% in the third quarter. Vaughan David Investments Inc. IL now owns 864,076 shares of the biotechnology company’s stock valued at $20,893,000 after acquiring an additional 851,074 shares during the period. Finally, Virtu KCG Holdings LLC lifted its holdings in Galena Biopharma by 677.4% in the second quarter. Virtu KCG Holdings LLC now owns 224,050 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 195,230 shares during the period. 19.00% of the stock is currently owned by hedge funds and other institutional investors.
Galena Biopharma Company Profile
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
What are top analysts saying about Galena Biopharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galena Biopharma Inc. and related companies.